☰

Kerry O. Cresawn, Ph.D. - Publications

Affiliations: 
2004 University of Florida, Gainesville, Gainesville, FL, United States 
Area:
Genetics, Immunology, Animal Physiology Biology, Pathology
Tree Info Grants Similar researchers PubMed Report error

12 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2010 Mah CS, Falk DJ, Germain SA, Kelley JS, Lewis MA, Cloutier DA, DeRuisseau LR, Conlon TJ, Cresawn KO, Fraites TJ, Campbell-Thompson M, Fuller DD, Byrne BJ. Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 502-10. PMID 20104213 DOI: 10.1038/Mt.2009.305  0.745
2007 Mah C, Pacak CA, Cresawn KO, Deruisseau LR, Germain S, Lewis MA, Cloutier DA, Fuller DD, Byrne BJ. Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 501-7. PMID 17245350 DOI: 10.1038/Sj.Mt.6300100  0.801
2006 Mah C, Pacak CA, Cresawn KO, DeRuisseau LR, Germain S, Lewis MA, Fuller DD, Byrne BJ. 410. Physiological Correction of Glycogen Storage Disease Type II Using Adeno-Associated Virus Serotype 1 Vectors Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.473  0.799
2006 Pacak CA, Mah C, Cresawn KO, Lewis MA, Germain S, Byrne BJ. 28. rAAV2/9 Mediated Gene Delivery of Acid α-Glucosidase Corrects the Cardiac Phenotype in a Mouse Model of Pompe Disease Molecular Therapy. 13: S12. DOI: 10.1016/J.Ymthe.2006.08.040  0.807
2005 Mah C, Cresawn KO, Fraites TJ, Pacak CA, Lewis MA, Zolotukhin I, Byrne BJ. Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors Gene Therapy. 12: 1405-1409. PMID 15920463 DOI: 10.1038/Sj.Gt.3302550  0.774
2005 Cresawn KO, Fraites TJ, Wasserfall C, Atkinson M, Lewis M, Porvasnik S, Liu C, Mah C, Byrne BJ. Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid α-glucosidase in a model of glycogen storage disease type II Human Gene Therapy. 16: 68-80. PMID 15703490 DOI: 10.1089/Hum.2005.16.68  0.797
2005 Cresawn KO, Mah CS, Zolotukhin I, Lewis MA, Byrne BJ. 911. Comparison of rAAV Serotype, Promoter, and Treatment Age for the Correction of Glycogen Storage Disease Type II Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.454  0.751
2005 Cresawn KO, Mah CS, Fraites TJ, Lewis MA, Zolotukhin I, Byrne BJ. 909. Sustained Correction of Glycogen Storage Disease Type II by rAAV1 Vector-Mediated Gene Therapy Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.452  0.825
2005 Mah C, Cresawn KO, DeRuisseau LR, Fuller D, Byrne BJ. 354. Correction of Respiratory Function by Recombinant AAV1 Mediated Gene Therapy in a Murine Model of Glycogen Storage Disease Type II Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.357  0.779
2004 Mah C, Fraites TJ, Cresawn KO, Zolotukhin I, Lewis MA, Byrne BJ. A new method for recombinant adeno-associated virus vector delivery to murine diaphragm. Molecular Therapy : the Journal of the American Society of Gene Therapy. 9: 458-63. PMID 15006614 DOI: 10.1016/J.Ymthe.2004.01.006  0.765
2004 Cresawn KO, Raben N, Plotz PH, Pacak C, Glick A, Byrne BJ. 859. A Skin-Restricted Conditionally Expressing Mouse Model of Pompe Disease for Assessment of Gene and Enzyme Replacement Therapies Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.767  0.737
2004 Cresawn KO, Wasserfall C, Atkinson MA, Mah C, Fraites TJ, Zolotukhin I, Byrne BJ. 250. Cross-Correction in Pompe Mice after Immunomodulation and Hepatic Delivery of Recombinant AAA5 and AAV8 Vectors Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.191  0.797
Show low-probability matches.